Trial Profile
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Zorifertinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Acronyms BLOOM
- Sponsors AstraZeneca
- 04 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Jul 2020 Planned End Date changed from 3 Jul 2020 to 20 Nov 2020.
- 24 Feb 2020 Planned End Date changed from 14 Feb 2020 to 3 Jul 2020.